TSVT

2seventy Bio, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website 2seventybio.com
Employees(FY) 425
ISIN US9013841070

Performance

-5.99%

-2.48%

-35.52%

-19.28%

-26.46%

YTD

-7.1%

Profile

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and chimeric antigen receptor-T cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Advanced Technical Analysis

Technical Analysis of TSVT 2024-12-20

The Moving Average Score of 10 indicates a strong bearish sentiment, while the Oscillators Score of 56 suggests a neutral stance. Overall, the Technical Score of 33 reinforces the bearish outlook, indicating that the stock may face downward pressure in the near term.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of TSVT

Stock Rank

Recent News & Updates

2024-11-11 18:00
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress(Businesswire)
2024-11-04 03:01
2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference(Businesswire)
2024-09-24 18:00
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance(Businesswire)
2024-08-28 19:00
2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference(Businesswire)
2024-08-06 19:00
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress(Businesswire)
2024-08-04 19:00
2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024(Businesswire)
2024-07-04 18:45
3 Hidden Stock Gems That Wall Street Is Overlooking(Investorplace)
2024-06-26 04:11
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million(Businesswire)
2024-05-22 19:00
2seventy bio to Participate in Upcoming Investor Conferences(Businesswire)
2024-05-12 03:24
5 Penny Stocks with Insider Buying in 2024(Insidermonkey)
2024-05-07 23:57
TSVT Stock Earnings: 2seventy bio Meets EPS, Misses Revenue for Q1 2024(Investorplace)
2024-05-07 20:15
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates(Zacks)
2024-05-07 19:00
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress(Businesswire)
2024-05-02 19:00
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024(Businesswire)
2024-04-23 22:01
2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?(Zacks)
2024-04-16 23:02
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why(Zacks)
2024-04-04 21:05
U.S. FDA Approves Bristol Myers Squibb and 2seventy bios Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy(Businesswire)
2024-03-31 19:30
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron(Businesswire)
2024-03-20 05:04
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors(Businesswire)
2024-03-15 06:27
FDA Advisory Committee Votes in Favor of Bristol Myers Squibbs and 2seventy bios Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy(Businesswire)
2024-03-06 20:10
2seventy bio, Inc. (NASDAQ:TSVT) Q4 2023 Earnings Call Transcript(Insidermonkey)
2024-03-04 18:53
TSVT Stock Earnings: 2seventy bio Misses EPS, Misses Revenue for Q4 2023(Investorplace)
2024-03-04 18:00
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress(Businesswire)
2024-03-03 19:56
Should You Buy 2seventy bio (TSVT) Ahead of Earnings?(Zacks)
2024-02-29 18:00
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences(Businesswire)
2024-02-26 19:00
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise(Newsfilecorp)
2024-02-05 03:05
2seventy bio to Participate in Upcoming Investor Conferences(Businesswire)
2024-02-04 17:59
Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study(Businesswire)
2024-01-31 19:27
2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains?(Zacks)
2024-01-30 22:11
2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up(Zacks)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.